Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm
Top Cited Papers
- 15 July 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (14) , 7337-7348
- https://doi.org/10.1128/jvi.00110-09
Abstract
The development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV-1)infected individuals with broad and potent HIV-1-specific neutralizing antibody responses is an important step toward the discovery of critical neutralization targets for rational AIDS vaccine design. In this study, samples from HIV-1-infected volunteers from diverse epidemiological regions were screened for neutralization responses using pseudovirus panels composed of clades A, B, C, and D and circulating recombinant forms (CRFs). Initially, 463 serum and plasma samples from Australia, Rwanda, Uganda, the United Kingdom, and Zambia were screened to explore neutralization patterns and selection ranking algorithms. Samples were identified that neutralized representative isolates from at least four clade/CRF groups with titers above prespecified thresholds and ranked based on a weighted average of their log-transformed neutralization titers. Linear regression methods selected a five-pseudovirus subset, representing clades A, B, and C and one CRF01_AE, that could identify top-ranking samples with 50% inhibitory concentration (IC(50)) neutralization titers of >= 100 to multiple isolates within at least four clade groups. This reduced panel was then used to screen 1,234 new samples from the Ivory Coast, Kenya, South Africa, Thailand, and the United States, and 1% were identified as elite neutralizers. Elite activity is defined as the ability to neutralize, on average, more than one pseudovirus at an IC(50) titer of 300 within a clade group and across at least four clade groups. These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design.Keywords
This publication has 70 references indexed in Scilit:
- Adjuvanted H5N1 vaccine induces early CD4+T cell response that predicts long-term persistence of protective antibody levelsProceedings of the National Academy of Sciences, 2009
- Development of hepatitis C virus vaccines: challenges and progressExpert Review of Vaccines, 2009
- Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2009
- Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing AntibodiesJournal of Virology, 2009
- Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and CJournal of Virology, 2008
- Antibody-Based HIV-1 Vaccines: Recent Developments and Future DirectionsPLoS Medicine, 2007
- Age?Dependent Differences in IgG Isotype and Avidity Induced by Measles Vaccine Received during the First Year of LifeThe Journal of Infectious Diseases, 2007
- Structural definition of a conserved neutralization epitope on HIV-1 gp120Nature, 2007
- HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sitesNature, 2002
- LYMPHADENOPATHY ASSOCIATED VIRUS IN AIDS, LYMPHADENOPATHY ASSOCIATED SYNDROME, AND CLASSIC KAPOSI PATIENTS IN GREECEThe Lancet, 1984